The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (BEV)-based therapy in the treatment of recurrent glioblastoma (GBM) in patients (PTS) treated at a Brazilian cancer center.
Rodrigo Ramella Munhoz
No relevant relationships to disclose
Maria Ignez Freitas Melro Braghiroli
No relevant relationships to disclose
Juliana Florinda De Mendonga Rego
No relevant relationships to disclose
Paulo Marcelo Hoff
No relevant relationships to disclose
Olavo Feher
No relevant relationships to disclose
Artur Katz
No relevant relationships to disclose